Results 251 to 260 of about 898,450 (282)
Prescription Support Practice for Pharmacy Students: Pre-Post Educational Intervention Study.
JMIR Med EducAizawa F +10 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Geriatric Clinical Pharmacology
Cardiology Clinics, 1986Age-related physiologic changes may significantly alter drug disposition and dynamics in the elderly. This is especially important for cardiovascular drugs, because they are used with such high frequency in the geriatric population. Alterations in the pharmacokinetics and pharmacodynamics of several drugs used to treat cardiovascular disease have been ...
M L, Rocci, P H, Vlasses, W B, Abrams
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1989
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire +5 more sources
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire +5 more sources
Clinical Pharmacology of Inodilators
Journal of Cardiovascular Pharmacology, 1989Recent advances in our knowledge of heart failure have shown that both a central and a peripheral factor are involved in this syndrome. Therefore, the ideal drug should combine the properties of a positive inotropic agent with those of a peripheral vasodilator; many drugs recently introduced into clinical practice have been shown to present both of ...
DEI CAS, Livio +2 more
openaire +3 more sources
Clinical Pharmacology of Cilazapril
Drugs, 1989In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.
C H, Kleinbloesem +3 more
openaire +3 more sources
Investigative Clinical Pharmacology
Clinical Pharmacology & Therapeutics, 2011Clinical pharmacology is an essential discipline in the development of new medicines, but the closely specified requirements of pharmaceutical industry protocols and regulatory reviewers have limited the opportunities for curiosity-driven research. Realization is growing that there is so much that is not known about the mechanisms underlying human ...
openaire +2 more sources
2022
This chapter provides an overview of the general principles and miscellaneous topics of clinical pharmacology that are relevant to pain medicine. This involves the World Health Organization (WHO) analgesic ladder which is mainly used for acute and cancer pain.
Sabina Bachtold +6 more
openaire +1 more source
This chapter provides an overview of the general principles and miscellaneous topics of clinical pharmacology that are relevant to pain medicine. This involves the World Health Organization (WHO) analgesic ladder which is mainly used for acute and cancer pain.
Sabina Bachtold +6 more
openaire +1 more source
Rapacuronium: clinical pharmacology
European Journal of Anaesthesiology, 2001The need for a rapid-acting non-depolarizing neuromuscular blocking agent with a short duration of action resulted in the synthesis of rapacuronium. The onset of maximum block with rapacuronium occurs in 60-90 s with doses of 1.5-2.5 mg kg-1 with a duration of clinical relaxation of 15-30 min.
R K, Mirakhur, K C, McCourt
openaire +2 more sources
Omapatrilat: Clinical pharmacology
Drugs of Today, 2000Omapatrilat is the most clinically advanced member of a new class of cardiovascular agents known as vasopeptidase inhibitors. Omapatrilat acts by inhibiting two key enzymes responsible for blood pressure regulation: neutral endopeptidase and angiotensin-converting enzyme.
openaire +2 more sources
Clinical pharmacology: Foscarnet
The American Journal of Medicine, 1992Foscarnet exerts its antiviral effects via reversible inhibition of viral polymerases. Pharmacodynamic data indicate that herpesvirus and human immunodeficiency virus replication is inhibited by therapeutically achievable concentrations of foscarnet; however, the concentrations of foscarnet required for such inhibition have been found to vary widely ...
openaire +2 more sources